About CellPhire
CellPhire is a company based in Rockville (United States) founded in 2006 by Richard Cliff. CellPhire has raised $25.3 million across 6 funding rounds from investors including Maryland Venture Fund. The company has 62 employees. CellPhire offers products and services including Thrombosomes® and Cryopreserved Platelets. CellPhire operates in a competitive market with competitors including Freeline, Disc Medicine, Keros Therapeutics, Jasper Therapeutics and Interius Biotherapeutics, among others.
- Headquarter Rockville, United States
- Employees 62
- Founders Richard Cliff
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website cellphire.com
- Social LinkedIn X
- Legal Name Cellphire, Inc
- Total Equity Funding$25.3M (USD)
in 6 rounds
- Latest Funding Round$3M (USD), Debt – Conventional
Nov 2025
- Investors
- Employee Count62
Products & Services of CellPhire
CellPhire offers a comprehensive portfolio of products and services, including Thrombosomes® and Cryopreserved Platelets.
Freeze-dried platelets for rapid bleeding control in emergencies.
Stored platelets providing extended shelf life for medical use.
Funding Insights of CellPhire
CellPhire has successfully raised a total of $25.3M across 6 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $3 million completed in November 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $25.3M
- Total Rounds 6
- Last Round Debt – Conventional — $3M
- First Round $1M
(Jun 2014)
- Investors Count 1
All 6 funding rounds of CellPhire with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2025 | $3M | Debt – Conventional | – | – | – |
| Aug 2022 | $5M | Series A | – | – | – |
| Apr 2021 | $15M | Series A | – | – | – |
| Jun 2017 | $3M | Series A | – | – | – |
| Aug 2016 | $1.3M | Seed | – | – | – |
| Jun 2014 | $1M | Seed | – | – |
1 investors in total: 1 institutional.
Investors in CellPhire
CellPhire has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Maryland Venture Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage investments are made in US companies across health sectors. | – | marylandventurefund.com | Columbia, United States |
Investor details for CellPhire
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CellPhire
22 people are tracked at CellPhire (12 in leadership, 8 in board & advisors, 2 in team); the tracked headcount is 62.
| Name | Role | Group |
|---|---|---|
Richard Cliff | Co-Founder & COO | Leadership |
Steve Willard | CEO | Leadership |
Stefanie Johns | Director Of Regulatory Affairs | Leadership |
G. Michael Fitzpatrick | Chief Scientific Officer | Leadership |
Michael Gaffney | CEO & President | Leadership |
Keith A. Moskowitz | VP of Discovery | Leadership |
Angela Howerton | VP of Finance, Treasurer & Controller | Leadership |
Ed Coles | VP, Program Management & New Product Development | Leadership |
Benjamin Kuhn | Associate Director of Discovery | Leadership |
Damien Bates | Chief Medical Officer | Leadership |
Robert Woods | Vice President Business Operations | Leadership |
Anya Derbij | VP, Clinical Operations | Leadership |
Roy A. Beveridge | Scientific Advisor | Board & advisors |
Terry B. Gernsheimer | Scientific Advisor | Board & advisors |
Thomas I.H. Dubin | Executive Chairman | Board & advisors |
Rafael Jorda | Director | Board & advisors |
David I. Hirsh | Director | Board & advisors |
James B. Peake | Director | Board & advisors |
Derek E. Woods | Director | Board & advisors |
Louis Katz | Scientific Advisor | Board & advisors |
2 more people are available in the full profile.
Complete people profiles for CellPhire
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of CellPhire
3 dated milestones of CellPhire across 19 years, from founding to its latest funding, stage changes and deals.
- Founded CellPhire is founded.
- Funding First funding round of $1.0M.
- Funding Latest funding round, Debt – Conventional, of $3.0M.
Competitors of CellPhire
CellPhire operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Freeline, Disc Medicine, Keros Therapeutics, Jasper Therapeutics and Interius Biotherapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| freeline.life | 2015 | Stevenage, United Kingdom | $273.69M | 152 | Gene therapy platform is developed for chronic disease treatments. | |
| discmedicine.com | 2017 | Cambridge, United States | $140M | 23 | Developer of therapeutics for the treatment of hematologic diseases | |
| kerostx.com | 2016 | Lexington, United States | $90M | 136 | Small molecules are developed to treat hematologic and musculoskeletal disorders. | |
| jaspertx.com | 1999 | Redwood, United States | $84.1M | – | Developer of therapeutics for chronic diseases by targeting mast cells and stem cells | |
| interiusbio.com | 2020 | Philadelphia, United States | $129.03M | 25 | Developer of gene therapies for treating multiple diseases | |
| spotlighttx.com | 2017 | Hayward, United States | $80.67M | 32 | Cancer therapeutics are developed using targeted gene editing platforms. | |
| veralox.com | 2017 | Frederick, United States | $47.47M | 6 | Small molecules are developed for thrombosis and diabetes treatments. | |
| renibus.com | 2013 | Southlake, United States | $153.52M | – | Therapeutics for kidney diseases are developed by Renibus Therapeutics. |
Detailed competitors of CellPhire
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of CellPhire
The website of CellPhire (cellphire.com) receives about 1.9K visits a month.
- Monthly visits1.9K
▼ 32.6% vs previous month
Websites whose visitors overlap most with CellPhire. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| senseibio.com | 100% | 4.5K | #4,696,262 | View details | |
| immunomix.com | 99% | 2.7K | #5,105,289 | View details | |
celnovte.com | celnovte.com | 98% | – | #1,346,988 | – |
| americangene.com | 96% | 16.6K | #1,411,276 | View details | |
| macrogenics.com | 93% | 10.4K | #2,000,657 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for CellPhire
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Cellphire
Complete news archive for CellPhire
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to CellPhire
10 companies that operate in the same segment as CellPhire (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 300 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 194 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about CellPhire
CellPhire was founded in 2006 and raised its 1st funding round 8 years after it was founded.
CellPhire is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Steve Willard is the current CEO of CellPhire.
CellPhire is a funded company, having raised a total of $25.3M across 6 funding rounds to date. The company's 1st funding round was a Seed of $1M, raised on Jun 2014.
CellPhire has 62 employees.
CellPhire was founded in 2006 in Rockville, United States, within the biotechnology sector. Platelet-based therapeutics for hemostasis are developed, with the lead candidate Thrombosomes positioned as a hemostatic agent for acute radiation sickness treatment. Additional cellular therapies are pursued to meet needs in anti-thrombotic reversal and regenerative medicine, focusing on unmet clinical areas through innovative approaches.
CellPhire's top competitors include Keros Therapeutics, Disc Medicine and Freeline.
CellPhire offers Thrombosomes® and Cryopreserved Platelets.
CellPhire has 1 investor. Key investors include Maryland Venture Fund.
CellPhire operates through Cellphire, Inc.